The forefront for novel therapeutic agents based on the pathophysiology of lower urinary tract dysfunction: α-blockers in the treatment of male voiding dysfunction - How do they work and why do they differ in tolerability?

Journal of Pharmacological Sciences

Volumn 112, Issue 2, 2010, Pages 151-157

  Michel, Martin C ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

Alfuzosin; Benign prostatic hyperplasia; Doxazosin; Lower urinary tract; Tamsulosin; Terazosin

Indexed keywords

ALFUZOSIN; ALPHA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; DOXAZOSIN; TAMSULOSIN; TERAZOSIN;

BLADDER NECK STENOSIS; CARDIOVASCULAR DISEASE; DETRUSOR MUSCLE; DRUG EFFICACY; DRUG TOLERABILITY; HUMAN; LOWER URINARY TRACT SYMPTOM; MICTURITION DISORDER; NONHUMAN; PROSTATE HYPERTROPHY; SENSORY NERVE; SHORT SURVEY; SMOOTH MUSCLE RELAXATION; UROTHELIUM;

EID: 77249100398     PISSN: 13478613     EISSN: 13478648     Source Type: Journal    
DOI: 10.1254/jphs.09R15FM     Document Type: Short Survey

References (62)

1. Homma Y. Lower urinary tract symptomatology: its definition and confusion. Int J Urol. 2008;15:35-43.
2. Chapple CR, Roehrborn CG. A shifted paradigm for the further understanding, evaluation, and treatment of lower urinary tract symptoms in men: focus on the bladder. Eur Urol. 2006;49: 651-659.
3. 1-Adrenergic receptors and their inhibitors in lower urinary tract symptoms and benign prostatic hyperplasia. J Urol. 2004;171:1029-1035.
4. 1-adrenoceptor antagonists. BJU Int. 2005;95 Suppl 4:29-36.
5. Waddel JA. The pharmacology of the prostate. J Pharmacol Exp Ther. 1916;9:179-186.
6. Caine M, Pfau A, Perlberg S. The use of alpha-adrenergic blockers in benign prostatic obstruction. Br J Urol. 1976;48:225-263.
7. Caine M, Perlberg S, Meretyk S. A placebo-controlled doubleblind study of the effect of phenoxybenzamine in benign prostatic obstruction. Br J Urol. 1978;50:551-554.
8. Hedlund H, Andersson K-E. Effects of prazosin in patients with benign prostatic obstruction. J Urol. 1983;130:275-278.
9. Garcia-Sacristan A, Casanueva CR, Castilla C, Labadia A. Adrenergic receptors in the urethra and prostate of the horse. Res Vet Sci 1984;36:57-60.
10. Hieble JP, Caine M, Zalaznik E. In vitro characterization of the α-adrenoceptors in human prostate. Eur J Pharmacol. 1985; 107:111-117.
11. 1- adrenoceptor subtypes. Naunyn Schmiedebergs Arch Pharmacol. 1995;352:1-10.
12. Price DT, Schwinn DA, Lomasney JW, Allen LF, Caron MG, Lefkowitz RJ. Identification, quantification, and localization of mRNA for three distinct alpha 1 adrenergic receptor subtypes in human prostate. J Urol. 1993;150:546-551.
13. 1-adrenoceptor subtypes and in human prostate. J Auton Pharmacol. 1996;16:21-28.
14. 2- and β-adrenoceptors in the urinary bladder, urethra and prostate. Br J Pharmacol. 2006;147: S88-S119.
15. 1-adrenoceptors in vascular smooth muscle. Br J Pharmacol. 1990;99:197-201.
16. 1L-adrenoceptor-mediated response in isolated preparations of the mouse prostate. Br J Pharmacol. 2008;155: 103-109.
17. Levin RM, Haugaard N, O'Connor O, Buttyan R, Das A, Dixon JS, Gosling JA. Obstructive response of human bladder to BPH vs. rabbit bladder response to partial outlet obstruction: a direct comparison. Neurourol Urodyn. 2000;19:609-629.
18. Taylor J, Harrison SCW, Assassa RP, McGrother CW. The pattern and progression of lower urinary tract symptoms after transurethral prostatectomy compared with those seen in the general population. Eur Urol. 2007;51:1023-1030.
19. 1 -adrenoceptors and native tissues. Mol Pharmacol. 1995;48: 250-258.
20. 1-adrenoceptor subtypes in the aetiology of LUTS. Eur Urol Suppl. 2002;1:5-13.
21. Kortmann BBM, Floratos DL, Kiemeney LALM, Wijkstra H, de la Rosette JJMCH. Urodynamic effects of alpha-adrenoceptor blockers: a review of clinical trials. Urology. 2003;62:1-9.
22. 1-adrenoceptor antagonists improve lower urinary tract symptoms by reducing bladder outlet resistance? Neurourol Urodyn. 2008;27:226-230.
23. Thomas AW, Cannon A, Bartlett E, Ellis-Jones J, Abrams P. The natural history of lower urinary tract dysfunction in men: minimum 10-year urodynamic followup of transurethral resection of prostate for bladder outlet obstruction. J Urol. 2005;174: 1887-1891.
24. Michel MC, de la Rosette JJMCH. Medical treatment of lower urinary tract symptoms suggestive of benign prostatic hyperplasia. Eur Urol Suppl. 2009;8:496-503.
25. Robinson D, Cardozo L, Terpstra G, Bolodeoku J. A randomized double-blind placebo-controlled multicentre study to explore the efficacy and safety of tamsulosin and tolterodine in women with overactive bladder syndrome. BJU Int. 2007;100:840-845.
26. Wilde MI, Fitton A, McTavish D. Alfuzosin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in benign prostatic hyperplasia. Drugs. 1993;45: 410-429.
27. Soeishi Y, Kobori M, Kobayashi S, Higuchi S, Arima H, Sullivang HR, et al. Absorption, distribution and excretion of 14 C-tamsulosin hydrochloride in rats and dogs. Pharmacometrics. 1990;40: 101-109.
28. Michel MC, Barendrecht MM. Physiological and pathological regulation of the autonomic control of urinary bladder contractility. Pharmacol Ther. 2008;117:297-312.
29. 1- and β-adrenoceptor expression and function. Neurourol Urodyn. 2009;28:349-355.
30. Recio P, Orensanz LM, Martinez MP, Navarro-Dorado J, Bustamente S, Garcia-Sacristan A, et al. Noradrenergic vasoconstriction of pig prostatic small arteries. Naunyn Schmiedebergs Arch Pharmacol. 2008;376:397-406.
31. 1D adrenergic receptors in the rat urothelium facilitates the micturition reflex. J Urol. 2006;175: 358-364.
32. Kaplan SA, Roehrborn CG, Rovner ES, Carlsson M, Bavendamm T, Guan Z. Tolterodine and tamsulosin for treatment of men with lower urinary tract symptoms and overactive bladder. A randomized controlled trial. J Am Med Assoc. 2006;296:2319-2328.
33. Lee K-S, Lee HW, Han DH. Does anticholinergic medication have a role in treating men with overactive bladder and benign prostatic hyperplasia? Naunyn Schmiedebergs Arch Pharmacol. 2008;377:491-501.
34. Michel MC, Chapple CR. Comparison of the cardiovascular effects of tamsulosin oral controlled absorption system (OCAS® ) and alfuzosin prolonged release (XL). Eur Urol. 2006;49: 501-509.
35. Nickel JC, Sander S, Moon TD. A meta-analysis of the vascularrelated safety profile and efficacy of α-adrenergic blockers for symptoms related to benign prostatic hyperplasia. Int J Clin Pract. 2008;62:1547-1559.
36. Michel MC, Flannery MT, Narayan P. Worldwide experience with alfuzosin and tamsulosin. Urology. 2001;58:508-516.
37. Michel MC, Mehlburger L, Bressel H-U, Schumacher H, Schäfers RF, Goepel M. Tamsulosin treatment of 19,365 patients with lower urinary tract symptoms: does comorbidity alter tolerability? J Urol. 1998;160:784-791.
38. Guimaraes S, Moura D. Vascular adrenoceptors: an update. Pharmacol Rev. 2001;53:319-356.
39. 1-adrenergic receptors by vessel bed and age. Circulation. 1999;100:2336-2343.
40. Görnemann T, Jähnichen S, Schurad B, Latte KP, Horowski R, Tack J, et al. Pharmacological properties of a wide array of ergolines at functional alpha 1 -adrenoceptor subtypes. Naunyn Schmiedebergs Arch Pharmacol. 2008;376:321-330.
41. Chen H, Fetscher C, Schäfers RF, Wambach G, Philipp T, Michel MC. Effects of noradrenaline and neuropeptide Y on rat mesenteric microvessel contraction. Naunyn Schmiedebergs Arch Pharmacol. 1996;353:314-323.
42. 1-adrenoceptor subtypes in human subcutaneous resistance arteries. J Pharmacol Exp Ther. 2001;299:729-734.
43. van Kerrebroeck P, Jardin A, Laval K-U, van Cangh P, ALFORTI Study Group. Efficacy and safety of a new prolonged release formulation of alfuzosin 10 mg once daily versus alfuzosin 2.5 mg thrice daily and placebo in patients with symptomatic benign prostatic hyperplasia. Eur Urol. 2000;37:306-313.
44. Kirby RS, Andersen M, Gratzke P, Dahlstrand C, Hoye K. A combined analysis of double-blind trials of the efficacy and tolerability of doxazosin-gastrointestinal therapeutic system, doxazosin standard and placebo in patients with benign prostatic hyperplasia. BJU Int. 2001;87:192-200.
45. Chapple CR, Al-Shukri SH, Gattegno B, Holmes S, Martinez-Sagarra JM, et al. Tamsulosin oral controlled absorption system (OCAS) in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia (LUTS/BPH): efficacy and tolerability in a placebo and active comparator controlled phase 3a study. Eur Urol Suppl. 2005;4:33-44.
46. 1-adrenoceptor antagonism of tamsulosin oral controlled absorption system (OCAS) and modified release (MR) formulations. Eur Urol Suppl. 2005;4: 45-52.
47. Michel MC, Korstanje C, Krauwinkel W, Shear M, Davies J, Quartel A. Cardiovascular safety of the oral controlled absorption system (OCAS) formulation of tamsulosin compared to the modified release (MR) formulation. Eur Urol Suppl. 2005;4:53-60.
48. Mottet N, Breessole F, Delmas V, Robert M, Costa P. Prostatic tissue distribution of alfuzosin in patients with benign prostatic hyperplasia following repeated oral administration. Eur Urol. 2003;44:101-105.
49. Romic I, Kiss T, Kisbenedek L, Kondas J, Torzsok F, Milak M, et al. Tamsulosin drug ratio in prostate versus free fraction in plasma supports pharmacokinetic (PK) contribution to its uroselectivity. J Urol. 2003;169 Suppl:288
50. Sato S, Ohtake A, Matsushima H, Saitoh C, Usuda S, Miyata K. Pharmacological effect of tamsulosin in relation to dog plasma and tissue concentrations: prostatic and urethral retention possibly contributes to uroselectivity of tamsulosin. J Pharmacol Exp Ther. 2001;296:697-703.
51. 1A- adrenoceptor-selective antagonist for treating benign prostatic hyperplasia: a results of a phase III randomized, placebo-controlled, double-blind study in Japanese men. BJU Int. 2006;98: 1019-1024.
52. 1-adrenoceptor antagonists on male sexual function. Drugs. 2006;66:287-301.
53. Hisasue S, Furuya R, Itoh N, Kobayashi K, Furuya S, Tsukamoto T. Ejaculatory disorder induced by alpha-1 adrenoceptor antagonists is not retrograde ejaculation but a loss of seminal emission. Int J Urol. 2006;13:1311-1316.
54. Buzelin JM, Fonteyne E, Kontturi MJ, Witjes WPJ, Khan A. Comparison of tamsulosin with alfuzosin in the treatment of patients with lower urinary tract symptoms suggestive of bladder outlet obstruction (symptomatic benign prostatic hyperplasia). Br J Urol. 1997;80:597-605.
55. Nordling J. Efficacy and safety of two doses (10 and 15 mg) of alfuzosin or tamsulosin (0.4 mg) once daily for treating symptomatic benign prostatic hyperplasia. BJU Int. 2005;95: 1006-1012.
56. 1A-adrenoceptor antagonist silodosin in men with signs and symptoms of benign prostatic hyperplasia: pooled results of 2 phase 3 studies. J Urol. 2009;181: 2634-2640.
57. 1A-adrenoceptor-selective antagonist for the treatment of benign prostatic hyperplasia. Exp Opin Invest Drugs. 2007;16: 1955-1965.
58. 1-Adrenoceptors are required for normal male sexual function. Br J Pharmacol. 2007;152:332-340.
59. 1-Adrenoceptors and ejaculatory function. Br J Pharmacol. 2007;152:289-290.
60. Chang DF, Campbell JR. Intraoperative floppy iris syndrome associated with tamsulosin. J Cataract Refract Surg. 2005;31: 664-673.
61. 1-adrenoceptor antagonists on pupil diameter and urethral tone in rabbits. Naunyn Schmiedebergs Arch Pharmacol. 2006;372:346-353.
62. Bell CM, Hatch WV, Fischer HD, Cernat G, Paterson JM, Gruneir A, et al. Association between tamsulosin and serious ophthalmic adverse events in older men following cataract surgery. J Am Med Assoc. 2009;301:1991-1996.